tradingkey.logo
tradingkey.logo

Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202

ReutersAug 5, 2025 1:31 PM

- Senti Biosciences Inc SNTI.O:

  • SENTI BIO DETERMINES RECOMMENDED PHASE 2 DOSE (RP2D) IN PHASE 1 STUDY OF SENTI-202 FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA

  • SENTI BIOSCIENCES INC - SENTI-202 WELL-TOLERATED, NO DOSE LIMITING TOXICITIES

  • SENTI BIOSCIENCES - EXPECTS TO REPORT CLINICAL DATA, INCLUDING EFFICACY & DURABILITY, FROM EXPANSION COHORT BEFORE YEAR-END

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI